AbbVie and Immunome Partner to Find New Cancer Treatments

Immunome and AbbVie announced a worldwide collaboration and option agreement to discover up to 10 new antibody-target pairs for treating three specific types of tumors using Immunome's technology.

Staff or Guest writer for The Dog of Wall Street.

2023-01-06 11:17

AbbVie (NYSE: ABBV) and Immunome have announced a collaboration to discover up to 10 novel antibody-target pairs for the treatment of three specific tumor types using Immunome's Discovery Engine. AbbVie and Immunome Partner to Find New Cancer Treatments
As part of the agreement, Immunome will grant AbbVie the option to purchase worldwide rights for the target-antibody pairs, and will receive an upfront payment of $30 million and potentially up to $70 million in platform access payments.

Immunome is also eligible for development and first commercial sale milestones of up to $120 million per target for certain products derived from the target-antibody pairs that AbbVie elects to purchase, as well as tiered royalties on global sales.

This collaboration expands AbbVie's oncology pipeline and allows Immunome to leverage AbbVie's development and commercialization expertise to bring new therapies to patients with life-threatening cancers.

See full press release here

Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Perf. YTD	%
52W high	%
52W low	-0%
PE Ratio
MKT Cap

Target Price	$0
# of Analysts
Last updated

Rate this article